FIRDAPSE Drug Patent Profile

When do Firdapse patents expire, and what generic alternatives are available?

Firdapse is a drug marketed by Catalyst Pharms and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has three patent family members in two countries.

The generic ingredient in FIRDAPSE is amifampridine phosphate. One supplier is listed for this compound. Additional details are available on the amifampridine phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Firdapse

Firdapse was eligible for patent challenges on November 28, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 25, 2037. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for FIRDAPSE

International Patents:	3
US Patents:	6
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FIRDAPSE

Paragraph IV (Patent) Challenges for FIRDAPSE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FIRDAPSE	Tablets	amifampridine phosphate	10 mg	208078	3	2022-11-28

US Patents and Regulatory Information for FIRDAPSE

FIRDAPSE is protected by six US patents.

This potential generic entry date is based on patent 10,626,088.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Catalyst Pharms	FIRDAPSE	amifampridine phosphate	TABLET;ORAL	208078-001	Nov 28, 2018		RX	Yes	Yes	11,274,332
Catalyst Pharms	FIRDAPSE	amifampridine phosphate	TABLET;ORAL	208078-001	Nov 28, 2018		RX	Yes	Yes	11,268,128
Catalyst Pharms	FIRDAPSE	amifampridine phosphate	TABLET;ORAL	208078-001	Nov 28, 2018		RX	Yes	Yes	11,274,331
Catalyst Pharms	FIRDAPSE	amifampridine phosphate	TABLET;ORAL	208078-001	Nov 28, 2018		RX	Yes	Yes	10,793,893

International Patents for FIRDAPSE

See the table below for patents covering FIRDAPSE around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2013003708
Canada	2840591	METHODES D'ADMINISTRATION DE 3,4-DIAMINOPYRIDINE (METHODS OF ADMINISTERING 3,4-DIAMINOPYRIDINE)
World Intellectual Property Organization (WIPO)	2017214504

FIRDAPSE (amifampridine): Investment Scenario and Fundamentals Analysis

Last updated: April 24, 2026

FIRDAPSE is a brand of amifampridine, a potassium-channel blocker used to treat Lambert-Eaton myasthenic syndrome (LEMS). The investment case is driven by (1) constrained competitive intensity in LEMS with symptomatic, non-curative therapy, (2) payer and access dynamics for a life-altering rare-disease drug, and (3) manufacturing and supply continuity for a specialized active ingredient and formulation.

---

What is the product, indication, and regulatory position?

Product

• Brand: FIRDAPSE
• Active ingredient: amifampridine
• Therapeutic class: Potassium channel blocker (symptomatic neuromuscular transmission improvement)

Indication

• Lambert-Eaton myasthenic syndrome (LEMS)

Regulatory posture (global positioning)

• FIRDAPSE is an established branded product in the LEMS space with recognized commercial launch history and ongoing market presence.

Reference pricing and access structure

• As a specialized rare-disease therapy, commercial trajectory depends more on persistence, titration dosing accuracy, nurse/neuromuscular specialist channel adoption, and formulary placement than on broad primary-care penetration.

---

How does demand typically form in LEMS and what does that mean for revenue durability?

LEMS is rare, so total addressable demand is finite. Investment fundamentals hinge on keeping the patient base stable and minimizing churn from tolerability, access interruptions, or side-effect-driven discontinuation.

Demand drivers

• Symptomatic need with ongoing use: Treatment is typically continued while benefits outweigh adverse effects.
• Specialist prescribing funnel: Neuromuscular specialists and academic centers influence share, with slower diffusion than common chronic therapies.
• Payer behavior in rare disease: Access is often secured through prior authorization pathways and patient support programs. Once established, switching costs tend to be high unless a clear clinical or economic advantage emerges.

Revenue durability implications

• High persistence potential: Rare-disease patients treated successfully often stay on therapy.
• Small market means small absolute unit growth: Total growth is usually incremental and can be capped by diagnosis rates and under-treatment.
• Sensitivity to product continuity: A supply constraint can quickly become a patient-care issue in a small population, amplifying revenue volatility.

---

What are the core competitive and substitution risks?

Competitive landscape dimensions that matter

1. Direct LEMS symptomatic alternatives
   • Other symptomatic options exist in LEMS practice, but none automatically eliminate amifampridine’s clinical value proposition.
2. Therapeutic interchangeability
   • If alternative regimens show stronger tolerability or easier administration, churn can rise.
3. Access and contracting
   • In rare disease, a payer contract or a center formulary decision can shift share even when clinical differences are modest.

Substitution vectors to model

• Within-class substitution: Switching to an alternative potassium-channel blockade regimen if outcomes or tolerability are perceived as superior.
• Real-world tolerability profile: GI or neurologic adverse events (typical class/titration considerations) can trigger discontinuation or dose reduction.
• Price and formulary mechanics: Bid/contract dynamics can pressure net price even if list price holds.

---

What is the investment scenario: base case, bear case, and bull case?

Assumption framework (investment scenario design)

• Market size is stable-to-slowly expanding due to rarity, with incremental demand from diagnosis improvement.
• Share is influenced by tolerability, supply reliability, and payer coverage.
• Net sales are more sensitive to access and persistence than to pure volume expansion.

Base case (status-quo competition, stable access)

• Patient persistence remains high after stabilization in the treated cohort.
• Coverage remains durable through continued payer acceptance and specialty channel relationships.
• Sales grow modestly through diagnosis capture and limited net share gain.

Primary upside levers

• Improved contracting terms and reduced patient friction (faster PA approvals, smoother refills).
• Higher treatment initiation among eligible patients.

Primary downside levers

• Rising co-pay burden or contracting erosion leading to delays in initiation or discontinuation.

Bear case (tolerability or access friction increases)

• Churn rises from adverse events or inconvenience in dosing and monitoring.
• Payer renegotiations reduce net price or restrict coverage for new starts.
• Supply interruptions cause missed refills and lost continuity.

Consequence

• Patient base contracts and/or growth slows sharply. In a rare disease, even modest churn produces outsized percentage sales pressure.

Bull case (share and access improve without major safety issues)

• Net price improves through favorable contracts or better list-to-net conversion.
• Specialist channel adoption expands as real-world outcomes align with expected benefit.
• Reduced friction increases treatment initiation and retention.

Consequence

• Sales outpace diagnosis-driven growth through share gain and improved persistence.

---

What fundamentals should investors underwrite: safety, manufacturing, and execution?

Safety and tolerability as a commercial variable

In symptomatic neuromuscular disease, safety does not only determine label compliance; it determines continuation. For an investor, tolerability is a revenue retention input.

Key underwriting points

• Dose titration discipline (reducing discontinuation rate).
• Management of class-related adverse effects and patient education systems.
• Risk mitigation execution in specialty settings.

Manufacturing and supply chain reliability

For a specialty oral therapy used by a relatively small patient base, supply reliability is a sales-critical operational KPI.

Key underwriting points

• Active ingredient availability and batch release continuity.
• Distributor and specialty pharmacy fill-rate performance.
• Contingency planning for regulatory or quality events.

Commercial execution fundamentals

• Specialty pharmacy readiness (refill adherence and reorder timing).
• Patient assistance effectiveness (reducing abandonment during coverage transitions).
• Specialist engagement (treatment initiation protocols and training).

---

What patent and exclusivity factors matter for FIRDAPSE (and what to model)?

FIRDAPSE’s long-term investment case must be evaluated through patent life remaining, formulation and manufacturing IP, and regulatory exclusivity milestones. The market risk is typically not a single patent expiration event. It is the combined effect of:

• patent expiry and generic entry timing,
• follow-on patent strength around formulation/process,
• payer willingness to switch.

Modeling requirement for investors

• Scenario-run the economic impact of generic entry on:
  • net price compression,
  • persistence and churn due to switching,
  • temporary supply capacity shifts,
  • distribution channel re-contracting.

---

How does valuation logic typically work for an established rare-disease brand?

Valuation for an established symptomatic rare-disease therapy often prices:

• durability of patient base (persistence),
• net sales stability (access and supply continuity),
• risk of generic substitution (patent and exclusivity runway),
• cost-to-serve (specialty pharmacy and patient support).

Practical valuation benchmarks

• Investors tend to anchor on a discounted cash flow view where:
  • near-term cash flows are stable-to-slightly growing in the base case,
  • downside is dominated by coverage erosion and churn,
  • tail risk is generic entry and pricing reset.

---

What KPIs determine whether the investment thesis is working?

Track these indicators quarterly to separate “marketing narrative” from cash generation:

1. New patient starts
   • Proxy for diagnosis capture and payer access expansion.
2. On-treatment persistence
   • Proxy for tolerability and dosing effectiveness.
3. Net-to-gross and payer mix
   • Proxy for contracting strength.
4. Fill-rate and backorder days
   • Proxy for supply reliability.
5. Switching activity
   • Proxy for competitive pressure and generic risk perception.

---

Key Takeaways

• FIRDAPSE (amifampridine) is a symptomatic LEMS therapy where the investment case is dominated by patient persistence, specialty access, and supply reliability, not by broad-market uptake.
• Base-case outcomes depend on durable payer coverage and low churn after initiation. Bear-case risk concentrates in access friction, tolerability-driven discontinuation, and supply disruption.
• Bull-case upside is real but narrower: it comes from share gain and improved net pricing, not from large market expansion.
• The strategic overhang for long-term valuation is patent/exclusivity runway and the economics of substitution at entry.

---

FAQs

1) What does FIRDAPSE treat?

FIRDAPSE treats Lambert-Eaton myasthenic syndrome (LEMS).

2) What is the active ingredient in FIRDAPSE?

The active ingredient is amifampridine.

3) Why does persistence matter so much for investing in FIRDAPSE?

LEMS is rare, so total demand is finite. Revenue depends on keeping treated patients on therapy over time.

4) What operational factors most affect FIRDAPSE revenue?

Supply continuity and specialty pharmacy fulfillment performance directly affect refill continuity in a small patient pool.

5) What is the largest structural risk to long-term value?

The largest structural risk is generic or substitution pressure after patent/exclusivity milestones, leading to net price compression and potential churn.

---

References

[1] FDA. “Drug Trials Snapshots: Firdapse.” U.S. Food and Drug Administration. https://www.fda.gov/ (accessed via FDA Drug Trials Snapshots page for FIRDAPSE).
[2] EMA. “Firdapse (amifampridine).” European Medicines Agency. https://www.ema.europa.eu/ (product information and assessment documents).
[3] DailyMed. “FIRDAPSE (amifampridine) tablet, for oral use.” U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/